{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:48:01Z","timestamp":1765806481659},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.dld.2005.04.002","type":"journal-article","created":{"date-parts":[[2005,5,15]],"date-time":"2005-05-15T01:40:42Z","timestamp":1116121242000},"page":"559-563","source":"Crossref","is-referenced-by-count":8,"title":["Prediction of response to infliximab in Crohn's disease"],"prefix":"10.1016","volume":"37","author":[{"given":"R.","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2005.04.002_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dld.2005.01.019","article-title":"Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study","volume":"37","author":"Orlando","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2005.04.002_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2005.04.002_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohn's disease","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2005.04.002_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease","volume":"15","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.002_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1572-0241.2004.04083.x","article-title":"Type of fistula determines response to infliximab in patients with fistulous Crohn's disease","volume":"99","author":"Parsi","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2005.04.002_bib7","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib8","first-page":"608","article-title":"Immunomodulators and \u2018on demand\u2019 therapy with infliximab in Crohn's disease: clinical experience with 400 infusions","volume":"98","author":"Kinney","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib9","first-page":"81","article-title":"Maintenance therapy versus episodic therapy with infliximab for Crohn's disease","volume":"1","author":"Ghosh","year":"2004","journal-title":"Nat Clin Practice Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2005.04.002_bib10","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S0002-9270(02)05260-7","article-title":"Strictures and response to infliximab in Crohn's disease","volume":"97","author":"Weinberg","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","article-title":"Response to infliximab is related to disease duration in paediatric Crohn's disease","volume":"18","author":"Lionetti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.002_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/art.20711","article-title":"C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept","volume":"52","author":"Buch","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2005.04.002_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.11168","article-title":"Polymorphism at position \u2212308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis","volume":"48","author":"Mugnier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2005.04.002_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with \u2212308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00008571-200210000-00002","article-title":"Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials","volume":"12","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.dld.2005.04.002_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","article-title":"NOD2\/CARD15 does not influence response to infliximab in Crohn's disease","volume":"123","author":"Vermeire","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2005.04.002_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.dld.2005.04.002_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2005.04.002_bib19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease","volume":"97","author":"Esters","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2005.04.002_bib20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","article-title":"ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease","volume":"120","author":"Taylor","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2005.04.002_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","article-title":"Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab","volume":"2","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.dld.2005.04.002_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","article-title":"Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab","volume":"20","author":"Pierik","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865805001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865805001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T08:26:03Z","timestamp":1548491163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865805001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1590865805001404"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2005.04.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}